Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Regulatory Developments On Pharmaceutical Intellectual Property Rights

This article was originally published in PharmAsia News

Executive Summary

China Intellectual Property News published an article introducing the laws and regulations on intellectual property rights for pharmaceuticals. Related laws cover patent, trademark, drug administration and anti-trust competition. Reviews are provided on regulatory provisions for new drugs approvals, protection of new medicines and technology transfer, administrative protection of pharmaceuticals, drug registration, and protection of TCM. The overview summarized the protection of pharmaceuticals from different aspects-protection terms, major content and newly revised items after China's entry to the World Trade Organization. Last year, the country ratified an amended version of WTO's Agreement of the Trade-Related Aspects of Intellectual Property Rights, which attempts to strike a balance between IPRs and public health. (Click here for more - Chinese Language)

You may also be interested in...

QUOTED. 25 November 2020. Ricki Chase.

The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.

US FDA’s 2020 User Fee Calendar Still Holds Promise Of Merry Novel Approval Count

The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.

PhRMA Sues To Block HHS Drug Importation Rule Citing Security, Safety, First Amendment Concerns

Complaint lists host of problems with implementation of the rule that allows states to sponsor programs to import certain prescription drugs from Canada; at least six states have enacted legislation to sponsor these programs.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts